Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-13 5:08 pm Sale | 2025-06-30 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 557,143 3.200% | -767,857 (-57.95%) | Filing History |
| 2025-07-15 4:30 pm Purchase | 2025-07-10 | 13D | ABVC BioPharma, Inc. ABVC | Eugene Jiang | 3,102,265 18.500% | 153,850 (+5.22%) | Filing History |
| 2025-06-03 4:01 pm Purchase | 2025-05-13 | 13D | ABVC BioPharma, Inc. ABVC | Eugene Jiang | 2,948,415 17.400% | 2,948,415 (New Position) | Filing History |
| 2025-02-14 5:13 pm Purchase | 2024-12-31 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 1,325,000 9.900% | 175,000 (+15.22%) | Filing History |
| 2024-11-14 7:33 pm Purchase | 2024-09-30 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 1,150,000 9.900% | 380,000 (+49.35%) | Filing History |
| 2024-02-13 7:59 pm Purchase | 2023-12-31 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 770,000 9.900% | 770,000 (New Position) | Filing History |
| 2023-08-07 4:01 pm Purchase | 2023-07-28 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 385,000 9.900% | 385,000 (New Position) | Filing History |
| 2022-07-12 5:00 pm Purchase | 2022-05-20 | 13D | ABVC BioPharma, Inc. ABVC | Jiang Shuling | 790,881 24.500% | 790,881 (New Position) | Filing |